세계의 원내감염 치료제 시장 : 약제 유형별, 투여 경로별, 감염 유형별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2025-2032년)
Hospital Acquired Infections Therapeutic Market, By Drug Type, By Route of Administration, By Infection Type, By Country, and By Region: Industry Analysis, Market Size, Market Share, and Forecast from 2025 to 2032
상품코드:1720007
리서치사:AnalystView Market Insights
발행일:2025년 03월
페이지 정보:영문 396 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
원내감염 치료제 시장 규모는 2024년 138억 7,500만 달러에 달했습니다. 이 시장은 2025-2032년 3.70%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예측됩니다.
원내감염이란 입원 중에 발병하고 입원 전에는 발병하지 않았던 감염을 말합니다. 원내감염 대책은 다양한 세척, 멸균, 소독 기술을 통해 원내감염을 예방하고 통제하는 것을 말합니다. 이러한 감염은 기구의 표면, 환자의 피부, 의료진의 2차 오염으로 인해 발생할 수 있습니다. 병원의 감염 관리는 질병의 전파를 감소 또는 제거하기 위해 수행됩니다.
세계의 원내감염 치료제 시장에 대해 조사했으며, 시장 개요와 함께 약제 유형별/투여 경로별/감염 유형별/국가별/지역별 동향, 시장에 진출한 기업 프로파일 등의 정보를 전해드립니다.
목차
제1장 원내감염 치료제 시장 개요
제2장 주요 요약
시장 내역
원내감염 치료제 시장 내역(약제 유형별)
원내감염 치료제 시장 내역(투여 경로별)
원내감염 치료제 시장 내역(감염 유형별)
원내감염 치료제 시장 내역(국가별)
원내감염 치료제 시장 내역(지역별)
경쟁 인사이트
제3장 원내감염 치료제 주요 시장 동향
원내감염 치료제 시장 성장 촉진요인
원내감염 치료제 시장 성장 억제요인
원내감염 치료제 시장 기회
원내감염 치료제 시장 향후 동향
제4장 원내감염 치료제 산업 연구
PEST 분석
Porter의 Five Forces 분석
성장 전망 매핑
규제 구조 분석
제5장 원내감염 치료제 시장 : COVID-19의 영향 분석
COVID-19 이전의 영향 분석
COVID-19 이후의 영향 분석
제6장 원내감염 치료제 시장 구도
원내감염 치료제 시장 점유율 분석(2024년)
주요 제조업체별 분석 데이터
기존 기업 분석
신규 기업 분석
제7장 원내감염 치료제 시장 - 약제 유형별
제8장 원내감염 치료제 시장 - 투여 경로별
제9장 원내감염 치료제 시장 - 감염 유형별
제10장 원내감염 치료제 시장 - 지역별
서론
북미
개요
미국
캐나다
유럽
개요
독일
이탈리아
영국
프랑스
러시아
네덜란드
스웨덴
폴란드
기타
아시아태평양
개요
인도
중국
일본
한국
호주
태국
인도네시아
필리핀
기타
라틴아메리카
개요
브라질
멕시코
아르헨티나
콜롬비아
기타
중동 및 아프리카
개요
사우디아라비아
아랍에미리트(UAE)
이스라엘
튀르키예
알제리
이집트
기타
제11장 주요 벤더 분석 - 원내감염 치료제 업계
경쟁 대시보드
기업 개요
Merck & Co.
Abbott
F. Hoffmann-La Roche
AbbVie
Allergan Plc
Eugia Pharma
Bayer
DAIICHI SANKYO COMPANY
Glenmark Pharmaceuticals
GSK
Hikma Pharmaceuticals
Melinta Therapeutics
Pfizer
Sanofi
Viatris
기타
제12장 360도 애널리스트의 견해
제13장 부록
LSH
영문 목차
영문목차
REPORT HIGHLIGHT
Hospital Acquired Infections Therapeutic Market size was evaluated at USD 13,875 million in 2024, rising at a CAGR of 3.70% between 2025 and 2032.
Hospital-acquired infections are infections that develop during hospitalisation that were not present before admission. Hospital-acquired infection control refers to the prevention and control of hospital-acquired infections through various cleaning, sterilisation, and disinfection techniques. These infections can be caused by cross-contamination of equipment surfaces, patient skin, and healthcare staff. Infection control in hospitals is used to reduce or eliminate disease transmission.
Rising healthcare costs are expected to drive the growth of the hospital-acquired infection control market. Healthcare expenditures are the total amount spent on healthcare-related services, products, and activities over a given period, usually on an individual, community, national, or global scale. As healthcare spending rises, hospitals and healthcare facilities are preparing to allocate more resources to the adoption of advanced infection prevention technologies, which include innovative solutions such as advanced disinfection systems, smart monitoring devices, and other technologies that improve overall infection control measures. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% in 2022. As a result, rising healthcare expenditure will drive future growth in the hospital-acquired infection control market.
The global release liner market is divided into four groups: Drug Type, Route of Administration, Infection Type, and geography.
The market is divided into four categories based on drug type: antibacterial drugs, antifungal drugs, antiviral drugs, and other drug types. Antibacterial drugs dominated the HAI therapeutics market in 2024. This dominance is because bacteria cause the vast majority of HAIs. As a result, a large proportion of HAIs are treated with antibacterial drugs. Furthermore, antibacterial therapy is the first line of treatment for all hospital-acquired infections. All patients infected with gram-positive and gram-negative pathogens must be treated with antibiotics. Empiric antibiotic therapy should be considered first based on a variety of risk factors for multidrug-resistant bacteria. Empiric antibiotic therapy is used to prevent complications like kidney damage, pyelonephritis, and bloodstream infections. Antibacterial therapy can be as short as 7 days or as long as 14-21 days.
Based on the type of infection, the market is divided into five segments: surgical site infections, urinary tract infections, bloodstream infections, ventilator-associated pneumonia, and other hospital infections. In 2024, the bloodstream infections segment held the largest market share. Bloodstream infections, also referred to as sepsis or bacteremia, are serious infections caused by bacteria or other pathogens entering the bloodstream. They are caused by a variety of microorganisms, including bacteria, viruses, and fungi, and can lead to serious complications like septic shock, organ failure, and death. Bloodstream infections are a major cause of morbidity and mortality in hospital settings, particularly among critically ill patients.
This market is geographically diversified across Europe, the Middle East, North America, Asia Pacific, and Africa, Latin America. The regions are further divided by the nations that bring commerce. In 2024, Europe dominated the market for HAI therapeutics, and this trend is expected to continue throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries, as well as the region's increasing approvals and launches of novel HAI therapeutics. Furthermore, the increased availability of novel hospital-acquired infection therapeutics in European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG is expected to support regional growth.
The HAIs therapeutics market in Asia Pacific is expected to grow significantly during the forecast period. This increase is attributed to the rising prevalence of chronic diseases in emerging economies like India and China, which has resulted in more hospitalisations. For example, Globocan reported that approximately 4,285,033 new cancer cases were diagnosed in China in 2018. Thus, the rising rate of HAIs and hospitalisations is expected to drive demand for HAI therapeutic drugs and support regional growth.
Major pharmaceutical companies such as Merck & Co., Abbott, F. Hoffmann-La Roche, AbbVie, and Allergan Plc compete in the Hospital Acquired Infections (HAIs) Therapeutic Market, with a focus on developing innovative antibiotics and antimicrobial therapies. Additionally, emerging biotech firms are investigating niche treatments such as monoclonal antibodies and bacteriophage therapy. Collaborations between established companies and startups are becoming more common as a way to improve drug development and address the rising prevalence of HAIs. As antibiotic resistance spreads, competition heats up, highlighting the need for effective treatment options and better patient outcomes in healthcare settings. For instance, in April 2024, Basilea Pharmaceutica International Ltd. reached a significant milestone when the FDA approved its new bloodstream infection treatment, Zevtera. This approval is a significant strategic move for Basilea, cementing its position as a market leader in HAI therapies. Zevtera's approval will broaden treatment options for severe infections, improving patient outcomes and strengthening Basilea's market presence through innovative solutions.
Recent Developments:
In October 2023, Spartan Medical Inc. launched a new campaign to increase awareness of surgical site infections (SSIs) and their consequences throughout the United States. This strategy aims to educate healthcare professionals and patients about the risks of SSIs and the importance of prevention, resulting in increased demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical's position in the infection control market by emphasising the company's dedication to addressing critical healthcare challenges.
In April 2022, Pfizer signed a definitive agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory syncytial virus (RSV). The acquisition will help Pfizer expand its presence in the antiviral therapeutics field and support its efforts to develop new treatments for RSV and other respiratory infections.
In December 2021, Merck, also known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that their antiviral drug molnupiravir has been granted Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of COVID-19. This is a significant step forward in the global effort to combat the COVID-19 pandemic, building on Merck's history of developing innovative drugs that address major health threats and improve patient outcomes.
SCOPE OF THE REPORT
This report's scope includes the following important market segments:
